Innovation in pharmaceuticals, medical devices, diagnostic and digital health technologies has transformed the way we deliver and manage treatments and organize healthcare systems. The challenges in uptake of integrated technologies may hinder patient access to new treatment options, potentially affecting patient outcomes and stifling innovation and commercial success in the European life sciences sector. To better understand the factors that can limit access to transformative technologies, CRA consultants, in collaboration with members of the American Chamber of Commerce to the European Union (AmCham EU) recently analyzed these challenges and opportunities.
To access the full article, click the link below.
IP Insights: Notable developments in IP litigation: April 2021
Sprint Communications Company LP v. WideOpenWest, Inc. et al., Case No. 1-18-cv-00361 (US District Court of Delaware) Sprint Communications filed lawsuits...